13 results about "Dextran Sulfate Sodium" patented technology

The invention relates to a rapid film-forming repair composition as well as a preparation method and application thereof. The rapid film-forming repair composition comprises a rapid film-forming repair component, a film softener, a pH regulator, a preservative and water, the film-forming repairing component is prepared from water temple porphyra polysaccharide, galactose araban and dextran sulfate sodium. Wherein the water temple laver polysaccharide, the galactose araban and the dextran sulfate sodium are combined for use and can interact, the synergistic promotion effect is achieved on the related skin improvement effect, and particularly, the effective components in the product can be promoted to rapidly form a film after being used, so that the skin is efficiently conditioned and repaired, and the skin quality is improved. The rapid film-forming repair composition provided by the invention also can relieve skin inflammation and redness, promote tissue regeneration and the like, is very suitable for skin care products, and is mild, non-irritant and good in stability.

The invention discloses an inflammatory bowel disease treatment method based on intestinal flora regulatory gene CD24 expression. According to the method, expression or functions of CD24 in host intestinal epithelial cells are up-regulated, the intestinal flora structure is adjusted, and intestinal inflammation is relieved. CD24 up-regulation can be realized by transfecting a CD24 gene overexpression vector, applying a transcription factor or a small molecule agonist or enhancing the activity of an endogenous gene by utilizing a gene editing technology. The CD24 is regulated and controlled, so that the proportion of the phylum firmicalis to the phylum bacteroides can be normalized, the enrichment of short-chain fatty acid producing flora is promoted, the activation of NF-kappa B and NLRP3 inflammasomes is inhibited, and the intestinal barrier function is enhanced. The DSS induced colitis model is established by drinking a 2-5% dextran sodium sulfate solution by a mouse, and simulates the pathological characteristics of human ulcerative colitis. Intervention modes include oral administration, enema or nanoparticle targeted delivery of the CD24 agonist pharmaceutical composition. The invention provides a new strategy for the treatment of inflammatory bowel diseases, especially ulcerative colitis, and has obvious dual curative effects of anti-inflammation and flora regulation.

This invention discloses the application of chestnut total burr ethanol extract in the preparation of anti-colitis drugs. In this invention, the chestnut total burr ethanol extract with anti-colitis properties is obtained by extracting chestnut total burrs with 70% ethanol. This chestnut total burr ethanol extract inhibits the production of LPS-induced pro-inflammatory mediators (NO) and pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) without cytotoxicity; it has a significant inhibitory effect on dextran sulfate sodium-induced colitis in mice, including slowing down weight loss, reducing mouse DAI scores, alleviating colonic tissue damage, downregulating the levels of IL-6, IL-1β, TNF-α, and MDA in mouse colonic tissue and serum, and enhancing the activities of CAT and SOD in mouse colonic tissue and serum. Therefore, the chestnut total burr ethanol extract has significant anti-inflammatory effects both in vivo and in vitro, and can be used to treat colitis.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ME1 in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The invention discloses an application of an ME1 inhibitor in preparation of drugs for preventing and / or treating inflammatory bowel diseases, and an application of a substance for detecting ME1 in preparation of drugs for diagnosing or detecting inflammatory bowel diseases. The action effect of ME1 * in disease treatment is evaluated through a mouse IBD model induced by dextran sodium sulfate DSS and trinitrobenzene sulfonic acid TNBS, so that a new strategy and method are provided for clinical intervention of IBD. In addition, the invention also clarifies the application of the ME1 as a high-specificity biomarker in IBD diagnosis, and further expands the comprehensive value of the ME1 in disease prevention and treatment.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

The application discloses a method for preparing high-value cellobiose from a medicine and food homologous Radix Millettiae and application of the high-value cellobiose. The method comprises the following steps: extracting cellulose from Radix Millettiae; optimizing a beta-glucanase enzymolysis process by using a response surface method; after the enzymolysis liquid is subjected to selective removal of glucose through yeast fermentation, the high-value cellobiose product is obtained through acetone precipitation and freeze-drying. The process condition is mild and environment-friendly, high-value utilization of agricultural waste is realized, the obtained cellobiose product has high purity, and an economic and effective approach is provided for large-scale production of cellobiose. Animal experiments prove that the cellobiose product has a significant relieving effect on colonitis induced by dextran sulfate sodium in mice, can effectively improve disease symptoms, reduce oxidative stress, repair intestinal barrier and regulate inflammatory response, and has a good application prospect in preparation of functional food or medicine for relieving colonitis and high-value utilization of Radix Millettiae.

The present invention relates to a composition for preventing, alleviating, or treating depression or anxiety disorder, the composition comprising a zeolite as an active ingredient, wherein the zeolite is excellent in increasing activity by alleviating depression or anxiety disorder in open-field tests and light-dark tests using a colitis animal model induced by dextran sulfate sodium salt (DSS), and is thus expected to be useful as a composition for preventing, alleviating, or treating depression or anxiety disorder.

The present invention relates to a composition for preventing, alleviating, or treating inflammatory bowel disease, the composition comprising a Cynomorium songaricum extract as an active ingredient. In an animal model of inflammatory bowel disease induced by dextran sulfate sodium (DSS), the Cynomorium songaricum extract increases body weight reduced due to DSS and reduces increased colon weight, and in particular, a mixture of the Cynomorium songaricum extract and a Gleditsia sinensis sting extract more significantly reduces a disease activity index increased by DSS administration than the Cynomorium songaricum extract or the Gleditsia sinensis sting extract alone. Thus, the composition can be highly effectively used in health functional foods or medicines for preventing, alleviating, or treating inflammatory bowel disease.

The application relates to the technical field of ulcerative colitis prevention and treatment, and particularly relates to application of avicularin in preparation of ulcerative colitis prevention and treatment drugs. Avicularin can effectively improve ulcerative colitis of mice caused by dextran sulfate sodium (DSS), can not only improve colon injury and reduce DAI index, but also can reduce expression of inflammatory cytokines and increase expression of intestinal mucosal barrier related proteins.

The invention provides application of gentisic acid in preparation of a medicine for treating inflammatory bowel diseases. The invention finds that gentisic acid has better improvement and treatment effects on inflammatory bowel diseases (especially ulcerative colitis) for the first time. The gentisic acid provided by the invention can remarkably improve symptoms of mouse acute ulcerative colitis induced by sodium dextran sulfate (DSS), for example, weight loss is relieved, the disease active index is reduced, colon shortening is relieved, and intestinal pathological injury is improved; and the treatment effect is possibly related to inhibition of Th1 cell differentiation and reduction of interferon-gamma (IFN-gamma) secretion by the gentisic acid. The invention discloses the effect of the natural compound gentisic acid in treating the inflammatory bowel disease, and expands the new application of the natural compound gentisic acid in pharmacology, new drug research and development and clinical treatment.

The invention provides a non-oxygen dependent type photodynamic nano material with a function of targeting M1 macrophages and application of the non-oxygen dependent type photodynamic nano material. The non-oxygen dependent type photodynamic nano material comprises chitosan nano particles coated with porphyrin supramolecules and dextran sulfate sodium salt. The material regulates LSG excessive activation through a neural immune strategy of M1 macrophages in selective apoptosis left stellate ganglion (LSG), so as to prevent and treat malignant arrhythmia after myocardial infarction.

The invention relates to application of licraside and a pharmaceutical composition for preventing or treating intestinal epithelial cell injury, and relates to the field of drug development. The licraside is used for preparing a medicine for preventing or treating intestinal epithelial cell injury. The Licraside disclosed by the invention can be used for repairing intestinal epithelial cell injury and has a protective effect on a dextran sodium sulfate induced cell inflammation model; the blank of existing licraside research is filled, and an experimental basis is provided for further development of new drugs.

The present invention relates to a composition for preventing, alleviating, or treating intestinal fibrosis, the composition comprising zeolite as an active ingredient. The zeolite according to the present invention is highly effective in reducing the thickness of intestinal tissue and the accumulation of collagen in intestinal tissue and reducing the expression level of a gene related to fibrosis in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of an ɑ-smooth muscle actin (ɑ-SMA) protein in an intestinal fibrosis cell model induced by TGF-β.